Cargando…

Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months

The authors present a case of a 53-years-old non-smoker Caucasian female who was diagnosed with lung adenocarcinoma (stage IA) and underwent surgical resection in 2002. Five years later, the tumor relapsed (stage IV disease) and she initiated chemotherapy with carboplatin, gemcitabine and bevacizuma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonçalves, Ivone, Ladeira, Inês, Castro, Ana, Antunes, Ana, Barroso, Ana, Parente, Bárbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920415/ https://www.ncbi.nlm.nih.gov/pubmed/26029502 http://dx.doi.org/10.1016/j.rmcr.2013.06.003

Ejemplares similares

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
por: Dong, Jiang-Kai, et al.
Publicado: (2018)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum
por: Dong, Jiang-Kai, et al.
Publicado: (2021)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report
por: Wu, Ka, et al.
Publicado: (2019)

Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation
por: Liu, Jing, et al.
Publicado: (2016)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
por: Kibirova, Albina, et al.
Publicado: (2019)

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
por: Isla, Dolores, et al.
Publicado: (2016)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

Dyspnea and Wheezing: Still a Challenge for Pulmonologists
por: Castro, Ana Sofia, et al.
Publicado: (2012)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation
por: Kim, Jung Soo, et al.
Publicado: (2017)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
por: Copeman, Michael
Publicado: (2008)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
por: ISHII, HIDENOBU, et al.
Publicado: (2014)

Erlotinib Promotes Ligand-Induced EGFR Degradation in 3D but Not 2D Cultures of Pancreatic Ductal Adenocarcinoma Cells
por: Betriu, Nausika, et al.
Publicado: (2021)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
por: Walleser, Silke, et al.
Publicado: (2012)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
por: Sueangoen, Natthaporn, et al.
Publicado: (2020)

Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib
por: Shahriari, Saeedeh, et al.
Publicado: (2022)

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
por: SUTANDYO, Noorwati, et al.
Publicado: (2019)

Minocycline-Induced Hyperpigmentation in a Patient Treated with Erlotinib for Non-Small Cell Lung Adenocarcinoma
por: Bell, Ann T., et al.
Publicado: (2017)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib
por: Takeda, Masayuki, et al.
Publicado: (2014)

T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review
por: Kusaba, Yusaku, et al.
Publicado: (2022)

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
por: Markóczy, Zsolt, et al.
Publicado: (2018)

Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib
por: Yokoyama, Akira, et al.
Publicado: (2018)

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
por: Jiang, Ye, et al.
Publicado: (2018)

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
por: Park, Jin H., et al.
Publicado: (2012)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
por: Topcu, Atakan, et al.
Publicado: (2022)

ODP359 Thyrotropin secreting pituitary microadenoma and lung adenocarcinoma treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) Erlotinib and Osimertinib: a case report
por: Di Ieva, Antonio, et al.
Publicado: (2022)

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib
por: Bryce, Alan H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_apqt1nf3hd1a56ko3rpf7nhko8